An mRNA Influenza Vaccine — Could It Deliver?

The article explores the feasibility and promise of a multivalent mRNA influenza vaccine, building on the technological advancements seen during the Covid-19 pandemic. It discusses the use of nucleoside-modified mRNA formulations to target all 20 known hemagglutinin (HA) subtypes of influenza viruses. Results from preclinical trials in mice and ferrets show robust immune responses and protection against matched strains, though limited efficacy against mismatched strains. The piece also highlights potential side effects, regulatory considerations, and the global equity impact of mRNA-based vaccine platforms.

The article explores the feasibility and promise of a multivalent mRNA influenza vaccine, building on the technological advancements seen during the Covid-19 pandemic. It discusses the use of nucleoside-modified mRNA formulations to target all 20 known hemagglutinin (HA) subtypes of influenza viruses. Results from preclinical trials in mice and ferrets show robust immune responses and protection against matched strains, though limited efficacy against mismatched strains. The piece also highlights potential side effects, regulatory considerations, and the global equity impact of mRNA-based vaccine platforms.